Valganciclovir

Valganciclovir (Valcyte) is an antiviral medication mostly used to treat cytomegalovirus infections. It is active against a number of herpesviruses.

Chronic Fatigue Syndrome
Valganciclovir (Valcyte) is used off-label to treat patients with ME/CFS. Studies have shown mixed evidence of efficacy.

Valganciclovir (Valcyte) may improve systems by via its broad spectrum antiviral activity against latent herpesviruses, which may reactivate in immunocompromised patients, including ME/CFS patients.

Valganciclovir became of additional interest as a potential ME/CFS treatment, particularly as an anti-inflammatory, when a 2014 study in mice suggested gancyclovir (the compound that valganciclovir converts to) reduced microglial activation; ME/CFS patients have been shown to have chronic activation of microglia. However follow-up mice studies and in vitro research found gancyclovir did not reduce microglial activation.

In a 2013 study by Montoya, et al, some improvement using valganciclovir was reported in a subset of ME/CFS patients with elevated IgG antibody titers against HHV-6 and EBV.

Notable Studies

 * 2013, Randomized Clinical Trial to Evaluate the Efficacy and Safety of Valganciclovir in a Subset of Patients With Chronic Fatigue Syndrome (Full text)
 * 2012, Response to valganciclovir in chronic fatigue syndrome patients with human herpesvirus 6 and Epstein-Barr virus IgG antibody titers. (Full text)

Learn more

 * 2016, Valganciclovir antiviral and CFS